-+ 0.00%
-+ 0.00%
-+ 0.00%

Castle Biosciences says JAAD study validates integrated DecisionDx-SCC test in high-risk skin cancer cohort of 572 patients

PUBT·09/09/2026 20:31:09
Listen to the news
Castle Biosciences says JAAD study validates integrated DecisionDx-SCC test in high-risk skin cancer cohort of 572 patients
  • Castle Biosciences highlighted a JAAD-published multicenter validation study of its integrated DecisionDx-SCC test for high-risk cutaneous SCC.
  • The study found the updated test improved risk stratification versus standard staging, supporting clearer treatment intensity and follow-up decisions.
  • Findings indicated the lowest-risk result could support de-escalation, while the highest-risk result flagged patients more likely to benefit from adjuvant radiation.
  • The validation covered 572 patients, positioning the refined algorithm as a potential driver of adoption in high-risk SCC management workflows.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Castle Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609091630PR_NEWS_USPR_____DA43807) on September 09, 2026, and is solely responsible for the information contained therein.